Publications

• InspeCKD - Analysis of the use of diagnostics in patients at high risk for chronic kidney disease in German general practitioner (GP) practices

  Christoph Wanner, Elke Schaeffner, Thomas Frese, Christoph Weber, Philipp Stahl, Felix Scherg, Fabian Burckhardt, Ulrich Opfermann, Frank Radowsky, Frederik Mader

  PMID: 10.1007/s15006-024-3684-y Show Details link to full text
  Study

  inspeCKD

  Year

  2024

  Keywords

  • CKD

• New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma

  Maggie Banys-Paluchowski

  PMID: 10.1055/a-1850-9512 Show Details link to full text
  Study

  Year

  2023

  Keywords

  • HER2
  • breast cancer

• Breast Cancer and Genetic BRCA1/2 Testing in Routine Clinical Practice: Why, When and For Whom?

  Michael P. Lux, Peter A. Fasching

  PMID: 10.1055/a-1929-2629 Show Details link to full text
  Study

  Year

  2023

  Keywords

  • breast cancer

• Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81–8973): Final results of the global real-world study, TAURUS

  Cristina Santoro, Beng Fuh, Phu Quoc Le, Philip Maes, Rubén Berrueco, Eva Maria Mingot-Castellano, Sylvia von Mackensen, Claudia Tueckmantel, Jose Francisco Cabre-Marquez, Michael Wang

  PMID: 36192847 Show Details link to full text
  Study

  TAURUS

  Year

  2023

  Keywords

  • haemophilia A

• Incidental Pulmonary Nodules - What Do We Know in 2022

  Gerald Schmid-Bindert, Jens Vogel-Claussen, Sylvia Gütz, Joana Fink, Hans Hoffmann, Martin E. Eichhorn, Felix J.F. Herth

  PMID: 36228594 Show Details link to full text
  Study

  Year

  2022

  Keywords

  • lung cancer

• A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients with Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE

  C. Dejaco, T. Mueller, O. Zamani, U. Kurtz, S. Egger, J. Resch-Passini, A. Totzauer, B. Yazdani-Biuki, T. Schwingenschloegl, P. Peichl, A. Kraus, G. W. Naerr

  PMID: 35721062 Show Details link to full text
  Study

  GO ACTIVE

  Year

  2022

  Keywords

  • rheumatoid arthritis
  • psoriatic arthritis
  • axial spondyloarthritis
  • golimumab
  • QoL
  • WPAI

• Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.

  V. Müller, M. Banys-Paluchowski, T.W.P. Friedl, P.A. Fasching, A. Schneeweiss, A. Hartkopf, D. Wallwiener, B. Rack, F. Meier-Stiegen, J. Huober, M. Rübner, O. Hoffmann, L. Müller, W. Janni, P. Wimberger, B. Jäger, K. Pantel, S. Riethdorf, N. Harbeck, T. Fehm, DETECT study group

  PMID: 34839105 Show Details link to full text
  Study

  DETECT

  Year

  2021

  Keywords

  • breast cancer
  • liquid biopsy
  • HER2
  • oncology

• Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months.

  N. Teich, H. Grümmer, E. Jörgensen, T. Liceni, F. Holtkamp-Endemann, T. Fischer, S. Hohenberger

  PMID: 33845784 Show Details link to full text
  Study

  Go CUTE II

  Year

  2021

  Keywords

  • golimumab
  • ulcerative colitis
  • QoL
  • WPAI
  • HCRU

• Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn's Disease in a Real-Life Setting: Results of a Prospective Multicenter Study i

  N. Teich, M. Bläker, F. Holtkamp-Endemann, E. Jörgensen, A. Stallmach, S. Hohenberger

  PMID: 33850839 Show Details link to full text
  Study

  MC Productive

  Year

  2021

  Keywords

  • Crohn's disease
  • infliximab
  • QoL
  • WPAI
  • HRQoL

• Neoadjuvant and adjuvant end-points in health technology assessment in oncology.

  N. Harbeck, A. Schneeweiss, P. Thuss-Patience, K. Miller, C. Garbe, F. Griesinger, W. E. E. Eberhardt, J. P. Klussmann, B. Wollenberg, M. O. Grimm, T. Zander, D. Lüftner

  PMID: 33611103 Show Details link to full text
  Study

  AMNOG

  Year

  2021

  Keywords

  • immunotherapy
  • oncology